

Fernanda Tavares-Da-Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8335569/publications.pdf>

Version: 2024-02-01

15
papers

1,298
citations

840776

11
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

2247
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine Adjuvants: from 1920 to 2015 and Beyond. <i>Vaccines</i> , 2015, 3, 320-343.	4.4	488
2	The howâ€™s and whatâ€™s of vaccine reactogenicity. <i>Npj Vaccines</i> , 2019, 4, 39.	6.0	302
3	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	3.2	90
4	Vaccine safety evaluation: Practical aspects in assessing benefits and risks. <i>Vaccine</i> , 2016, 34, 6672-6680.	3.8	86
5	Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. <i>Expert Review of Vaccines</i> , 2018, 17, 619-634.	4.4	77
6	Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. <i>Vaccine</i> , 2013, 31, 1870-1876.	3.8	64
7	Adjuvant Systems for vaccines: 13â€™ years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. <i>Vaccine</i> , 2019, 37, 5670-5680.	3.8	45
8	Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. <i>Vaccine</i> , 2019, 37, 2004-2015.	3.8	42
9	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. <i>Vaccine</i> , 2019, 37, 2482-2493.	3.8	34
10	Safety assessment of adjuvanted vaccines: Methodological considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1814-1824.	3.3	26
11	Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. <i>Vaccine</i> , 2020, 38, 3489-3500.	3.8	20
12	Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials. <i>Drug Safety</i> , 2021, 44, 811-823.	3.2	10
13	An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine. <i>Drug Safety</i> , 2021, 44, 1341-1353.	3.2	5
14	Fourteen years of the Pregnancy Registry on maternal immunisation with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine. <i>Vaccine</i> , 2022, 40, 904-911.	3.8	5
15	Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology. <i>Drug Safety</i> , 2020, 43, 1223-1234.	3.2	4